Tenet Healthcare Corp.
THCHIGH VELOCITYFILING INTENSITYTenet Healthcare Corp. reads as an High Velocity (composite 78/100); Programmatic Roll-Up deploying $1B across 182 disclosed transactions, down 58% vs the prior cycle · primary market Healthcare, ranked #12 on disclosed spend.
Lens
Disclosed M&A capital (2023–2025)
$1.1B
vs $2.6B in 2020–2022
Disclosed transactions
182
3/3 active fiscal years in window
Buyer archetype
Programmatic Roll-Up
High recurring acquisition cadence, usually with many smaller targets.
Composite score
78
High Velocity dominates · Filing Intensity
Behavioral posture, nine reads.
Each index scores the issuer 0–100 against an EDGAR-anchored definition. Scores ≥ threshold elevate the issuer into the index's constituent set; the dominant index drives the masthead label.
Active Acquirer
Companies actively deploying disclosed capital into M&A
- $7.3B disclosed buyer spend
- Filed within 26d
Buyer Cadence
Buyer-side companies with recent filing activity
- Filed within 26d
- 441 8-Ks
Target Probability
Issuers showing target-side patterns from filings
- 31 activism filings
Spin/Carve
Issuers showing spin-off, carve-out, or sum-of-parts posture
- 31 activism filings
Pressure Watch
Issuers facing activism, governance, or control pressure
- 31 activism filings
- Latest activism 5.1y ago; heavily discounted
Distress Watch
Issuers showing financial-distress filing patterns
- 31 activism filings
Restatement Risk
Issuers with accounting-integrity flags from filings
- 4 non-reliance 8-Ks
- 1 auditor change
- 1 NT late filing
- Latest event 19y ago; heavily discounted
Capital Velocity
DominantIssuers with the highest filing-activity intensity
- 441 8-Ks
- Filed within 26d
- 5 form types
Quiet Power
Large issuers with low signal volume and clean disclosure cadence
- Enterprise value $26.6B
- 10-Q 26d ago
- 3 active signals
Capital cadence.
Ten-year disclosed M&A activity. Bars show spend ($MM); ticks show recorded transaction count. Disclosure tier annotated where v6 audited corpus carries an entry.
Disclosed spend $MM Disclosed transactions (right axis)Peak spend year: $1,220M · Peak count: 115
| FY | Disclosed buys | Disclosed spend | Avg ticket | Audited tier |
|---|---|---|---|---|
| 2025 | 36 | $308M | $9M | N/A |
| 2024 | 115 | $571M | $5M | N/A |
| 2023 | 31 | $224M | $7M | N/A |
| 2022 | 53 | $234M | $4M | N/A |
| 2021 | 100 | $1.2B | $12M | N/A |
| 2020 | N/A | $1.2B | N/A | N/A |
Strategy posture.
The buyer's playbook in terms of strategic archetype: what each disclosed move says about how they're deploying capital.
Archetype mix
- Geographic Expansion20%
- Bolt On20%
- Platform20%
- Horizontal Consolidation20%
- Tuck In20%
Strategy keywords
Terms recurring across recent 10-K acquisition disclosures.
- geographic_expansion
- bolt_on
- platform
- horizontal_consolidation
- tuck_in
Filing language.
Direct excerpts from acquisition disclosures and strategy sections: the verbs the buyer chose, in the filings they signed.
“We continue to focus on opportunities to expand our Ambulatory Care segment through acquisitions, organic growth, construction of new outpatient centers and strategic partnerships.”
“we acquired ownership interests in 56 fully operational UCCs and one telehealth center located in Arizona”
“we added over 35 ASCs to our portfolio through acquisitions of majority and minority ownership interests”
“we acquired controlling ownership interests in 20 ASCs in which we did not have a previous investment”
“we remain focused on opportunities to expand our Ambulatory Care segment through acquisitions”
Market context.
Where this issuer sits inside its SE-Cluster rollup wedge, with disclosed-spend rank plus trading comparables against the public peer set.
Primary market
Healthcare
- Market spend (2023–2025)
- $195B
- Market spend (2020–2022)
- $253.6B
- Recent vs prior
- −23%
- Issuer rank in market
- #12 of 391
- Share of market capital
- 0.8%
Valuation positioning
THC trades at a -6.9-turn discount to the Healthcare peer median of 12.9×.
- EV / Revenue
- 1.2×
- Net debt / EBITDA
- -0.6×
- Peer median EV / EBITDA
- 12.9×
Trading comparables
FMP market data · 2026-05-11
| Company | EV / EBITDA | EV / Rev | Net debt / EBITDA | Revenue | M&A 2023–2025 |
|---|---|---|---|---|---|
AbbVie Inc.ABBV | 23.4× | 6.7× | 3.1× | $62.8B | $18B |
| 17.2× | 0.9× | 1.9× | $449.7B | $28.1B | |
Amgen Inc.AMGN | 12.9× | 6.0× | 2.6× | $37.2B | $26.7B |
| 11.7× | 0.5× | 2.5× | $200.4B | $6.4B | |
| 9.3× | 1.9× | 2.8× | $76.4B | $1.3B | |
Tenet Healthcare Corp.THC | 6.1× | 1.2× | -0.6× | $21.5B | $1.1B |
Trading multiples from FMP market data; disclosed M&A spend from the SE-Cluster EDGAR 10-K corpus. Peer set = top disclosed buyers in Healthcare. Bars scaled to the highest EV/EBITDA in the set.
Target landscape.
Public-issuer targets that fit this buyer's archetype and target categories from filing-derived signal. Scores reflect cross-signal fit; reasons cite the EDGAR-anchored facts that drove the match.
No qualifying public-issuer targets surfaced from the current signal mix.
Stated target categories
No target categories enumerated in the audited corpus for this issuer.
Filing activity & signal stream.
Filing cadence and event-driven signals visible on EDGAR. The signal stream below is curated from restatement / spin-carve / activism categories, providing context for any near-term call.
Filing cadence
- 10-K (annual)312026-02-17
- 10-Q (quarterly)1052026-04-30
- 8-K (event)4412026-04-30
- Proxy / DEF 14A1352026-04-16
- Activism (13D / DFAN / PREC)312021-04-22
Signals on file
- critical
Non-reliance disclosure
2006-03-094 Item 4.02 filings on file; financial-statement non-reliance.
- elevated
Auditor change
2007-01-091 Item 4.01 filing on file; certifying accountant change.
- watch
Late-filing notice
2005-08-101 NT 10-K/10-Q filing on file.
- elevated
Activism on file
2021-04-2231 activist filings on file (13D, DFAN14A, PREC14A series).
- info
Signal
Serial acquisition history
- info
Signal
10-K strategy themes
- info
Signal
Restatement risk
Audited corpus.
No audited record on file for this CIK in the current v6 corpus.
This issuer has not been extracted into the v6 audited acquirer corpus yet. The brief above pulls from ranking-level aggregates and issuer-index signal only.